Oncolytics Biotech® Announces Clinical Supply Agreement to Evaluate Pelareorep in Combination with LOQTORZI® (toripalimab-tpzi) in Squamous Cell Anal Carci

Oncolytics Biotech remains in a high-risk, pre-revenue development phase characterized by significant R&D expenditures and a rapidly deteriorating balance sheet.
Price trend, volume and key moving averages
Trailing total returns as of 11/19/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 13, 2026 | -$0.08-46.8% vs -$0.05 | — vs — |
Q3 2026 Aug 12, 2026 | -$0.08-48.7% vs -$0.05 | — vs — |
Q2 2026 May 14, 2026 | -$0.08-60.0% vs -$0.05 | — vs — |
Q2 2026 Mar 30, 2026 | -$0.01+83.1% vs -$0.06 | — vs — |
Oncolytics Biotech® Announces Clinical Supply Agreement to Evaluate Pelareorep in Combination with LOQTORZI® (toripalimab-tpzi) in Squamous Cell Anal Carci

Oncolytics Biotech® Announces Clinical Supply Agreement to Evaluate Pelareorep in Combination with LOQTORZI® (toripalimab-tpzi) in Squamous Cell Anal Carci

SAN DIEGO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced translational data in heavily pretreated relapsed/refractory multiple myeloma patients, which will be presented at the 68th American Society of Hematology (“ASH”) Annual Meeting and Exposition. Title: Pelareorep induces innate and adaptive antiviral immune activation in relapsed/refractory multiple myeloma: Single-cell analysis from a Phase 1b/2 trial Abstract Number: 2183 Presentation Type: Poster Presentation Date: Saturday, December 12, 2026 Highlights from the abstract include: The Phase 1b/2 trial evaluated bortezomib (“BOR”), dexamethasone (“DEX”), and pembrolizumab (“Pemb”) in Cohort 1 and pelareorep plus BOR, DEX, and Pemb in Cohort 2 in patients with relapsed/refractory multiple myeloma.
Pelareorep-driven changes in the tumor microenvironment are associated with tumor responses and shrinkage Immune activation levels more than doubled in nearly all patients after one cycle of treatment Substantial increases in HPV-16-specific T cells and tumor-infiltrating lymphocytes observed when pelareorep is combined with a checkpoint inhibitor SAN DIEGO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced new translational data from an ongoing study showing pelareorep's ability to increase human papillomavirus (“HPV”)-16-specific T cell clones and tumor-infiltrating lymphocyte (“TIL”) clones in second-line or later squamous cell anal cancer (“SCAC”) patients at the Society for Immunotherapy of Cancer (“SITC”) 2026 Annual Meeting. Pelareorep combined with a checkpoint inhibitor generated promising efficacy signals in second-line or later SCAC, including more than doubling the objective response rate and increasing median duration of response by 50% compared to the current approved therapy in that patient population.
Benchmark ONCY against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Oncolytics Biotech Inc. (ONCY)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.44 | $56.31M | -2.15 | — | — | -7467.16% | — | |
| $33.17 | $6.85B | -13.47 | — | -7173.52% | -63.01% | — | |
| $27.55 | $1.83B | -7.00 | -78.63% | -275986.61% | -52.67% | — | |
| $34.42 | $1.18B | -6.64 | -43.89% | -339.67% | -29.31% | — | |
| $0.08 | $1.06M | -0.05 | 16.05% | -122.42% | — | — | |
| $443.89 | $239.57B | 25.81 | 9.92% | 24.12% | 85.59% | 2.13% |
Oncolytics Biotech Inc. (ONCY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Oncolytics Biotech Inc. (ONCY) SEC filings — annual & quarterly reports (10-K, 10-Q)
Nov 12, 2026·SEC
Nov 9, 2026·SEC
Nov 4, 2026·SEC
Mar 30, 2026·SEC
Get notified when ONCY posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Oncolytics Biotech Inc. (ONCY) stock FAQ — growth, dividends, profitability & financials explained
No. Oncolytics Biotech Inc. (ONCY) reported a net loss of $37.6M over the trailing twelve months.
Oncolytics Biotech Inc. (ONCY) had a return on equity (ROE) of -7467.2% in fiscal year 2025. A negative ROE means the company lost money over the period.
Oncolytics Biotech Inc. (ONCY) had negative free cash flow of $29.1M over the trailing twelve months.